Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study

We recruited consecutive patients with stage III epithelial ovarian, tubal, and peritoneal cancers who had optimal residual tumor after primary cytoreductive surgery and who received intraperitoneal chemotherapy between 2002 and 2012. Two propensity score-matched sample cohorts were created. We foun...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yen-Hou, Lu, Chien-Hsing, Yen, Ming-Shyen, Lee, Wai-Hou, Chang, Yi, Chang, Wei-Pin, Chuang, Chi-Mu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862156/
https://www.ncbi.nlm.nih.gov/pubmed/27160669
http://dx.doi.org/10.1186/s40880-016-0105-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862156/
https://www.ncbi.nlm.nih.gov/pubmed/27160669
http://dx.doi.org/10.1186/s40880-016-0105-3

Ejemplares similares